跳到正文
原文
Nature 健康护理主题·· 2026-10-16AI 评分53

目标试验模拟评估四个欧洲国家妊娠期 COVID-19 mRNA 疫苗的有效性

Target trial emulation of effectiveness of COVID-19 mRNA vaccination during pregnancy in four European countries

AI 导读

一项发表于 Nature Communications 的研究通过目标试验模拟评估四个欧洲国家妊娠期接种 COVID-19 mRNA 疫苗的有效性。该设计以观察性数据模拟随机试验,为孕期疫苗效果评估提供方法学参考。

正文

Acknowledgements

We acknowledge the significant scientific contributions of Professor Angela Lupattelli, who passed away during this study. Prof Lupattelli played an important role in the study’s design and contributed substantially to the handling of Norwegian data. Her dedication, insight, and expertise are highly appreciated. The authors thank Dr. Carlen Reyes, who contributed to the identification of NCOs; Dr. Alicia Abellan and colleagues, who developed and implemented the OMOP pregnancy extension table, which was instrumental in the development of this study; and Dr. Marissa Erin Leblanc for her valuable suggestions. We acknowledge English language editing by Dr. Jennifer de Beyer, Centre for Statistics in Medicine, NDORMS, University of Oxford. The corresponding author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Funding

BR and TD-S work for a research group that receives/received unconditional research grants from UCB, Johnson and Johnson, Innovative Medicines Initiative, and the European Medicines Agency, none of which relate to the content of this manuscript. DPA’s research group from the University of Oxford has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Gilead Science, and UCB Biopharma, none of which are related to this manuscript. FN has funding for this research from SciLifeLab / the Knut and Alice Wallenberg Foundation (KAW 2021-0010/VC2021.0018 and KAW 2020.0299/VC 2022.0008) and the Swedish Research Council (2021-05045 and 2021-05450). The overarching SCIFI-PEARL study (contributing Swedish data to the current analysis) through P.I. FN also has core funding from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (Avtal om Läkarutbildning och Forskning/Medical Training and Research Agreement), grants ALFGBG-938453, ALFGBG-971130, ALFGBG-978954, ALFGBG-1006729, a grant from FORTE (Research Council for Health, Working Life, and Welfare), grant 2024-01711, and previously from a joint grant from FORTE and FORMAS (Research Council for Environment, Agricultural Sciences and Spatial Planning), grant 2020-02828. Acquisition of the Norwegian data in this study was funded by Professor Nordeng’s EU-COVID-19 project, funded by the Norwegian Research Council’s COVID-19 Emergency Call (project no. 31270).

Author information

Author notes

  1. These authors contributed equally: Núria Mercadé-Besora, Berta Raventós.

  2. These authors jointly supervised this work: Hedvig Marie Egeland Nordeng, Talita Duarte-Salles.

Authors and Affiliations

  1. Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain

    Núria Mercadé-Besora, Berta Raventós, Agustina Giuliodori & Talita Duarte-Salles

  2. Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK

    Núria Mercadé-Besora, Theresa Burkard, Edward Burn, Martí Català & Daniel Prieto-Alhambra

  3. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands

    Berta Raventós, Daniel Prieto-Alhambra & Talita Duarte-Salles

  4. Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

    Nhung TH Trinh, Saeed Hayati & Hedvig Marie Egeland Nordeng

  5. School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Huiqi Li & Fredrik Nyberg

  6. Usher Institute, University of Edinburgh, Edinburgh, UK

    Daniel R. Morales

Authors

  1. Núria Mercadé-Besora
  2. Berta Raventós
  3. Nhung TH Trinh
  4. Huiqi Li
  5. Saeed Hayati
  6. Agustina Giuliodori
  7. Theresa Burkard
  8. Edward Burn
  9. Martí Català
  10. Daniel Prieto-Alhambra
  11. Daniel R. Morales
  12. Fredrik Nyberg
  13. Hedvig Marie Egeland Nordeng
  14. Talita Duarte-Salles

Corresponding author

Correspondence to Talita Duarte-Salles.

Ethics declarations

Competing interests

All authors have completed the ICMJE uniform disclosure form and declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work. FN reports research project support (paid to his institution, no personal fees) by Bayer, with no relation to the work reported here. FN owns some AstraZeneca shares. TB reports consultancy for Institut Biochimique SA, with no relation to the work reported here.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mercadé-Besora, N., Raventós, B., Trinh, N.T. et al. Target trial emulation of effectiveness of COVID-19 mRNA vaccination during pregnancy in four European countries. Nat Commun (2026). https://doi.org/10.1038/s41467-026-78469-x

Download citation

  • Received: 13 October 2025

  • Accepted: 19 September 2026

  • Published: 16 October 2026

  • DOI: https://doi.org/10.1038/s41467-026-78469-x

来源:Nature 健康护理主题 · nature.com